Novo Nordisk A/S Stock

Novo Nordisk A/S P/E 2024

Novo Nordisk A/S P/E

53.59

Ticker

NOVO B.CO

ISIN

DK0060534915

WKN

A1XA8R

As of Nov 1, 2024, Novo Nordisk A/S's P/E ratio was 53.59, a 81.66% change from the 29.5 P/E ratio recorded in the previous year.

The Novo Nordisk A/S P/E history

Novo Nordisk A/S Aktienanalyse

What does Novo Nordisk A/S do?

Novo Nordisk A/S is a Danish company specializing in the production of insulin and other diabetes medications. It was founded in 1923 and has its headquarters in Bagsværd, Denmark. Novo Nordisk is the world's largest manufacturer of insulin and one of the key players in the field of diabetes treatment. Novo Nordisk A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Novo Nordisk A/S's P/E Ratio

The Price to Earnings (P/E) Ratio of Novo Nordisk A/S is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Novo Nordisk A/S's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Novo Nordisk A/S is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Novo Nordisk A/S’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Novo Nordisk A/S stock

What is the price-to-earnings ratio of Novo Nordisk A/S?

The price-earnings ratio of Novo Nordisk A/S is currently 53.59.

How has the price-earnings ratio of Novo Nordisk A/S changed compared to last year?

The price-to-earnings ratio of Novo Nordisk A/S has increased by 81.66% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Novo Nordisk A/S high compared to other companies?

Yes, the price-to-earnings ratio of Novo Nordisk A/S is high compared to other companies.

How does an increase in the price-earnings ratio of Novo Nordisk A/S affect the company?

An increase in the price-earnings ratio of Novo Nordisk A/S would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Novo Nordisk A/S affect the company?

A decrease in the price-earnings ratio of Novo Nordisk A/S would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Novo Nordisk A/S?

Some factors that influence the price-earnings ratio of Novo Nordisk A/S are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Novo Nordisk A/S pay?

Over the past 12 months, Novo Nordisk A/S paid a dividend of 14.15 DKK . This corresponds to a dividend yield of about 1.83 %. For the coming 12 months, Novo Nordisk A/S is expected to pay a dividend of 14.94 DKK.

What is the dividend yield of Novo Nordisk A/S?

The current dividend yield of Novo Nordisk A/S is 1.83 %.

When does Novo Nordisk A/S pay dividends?

Novo Nordisk A/S pays a quarterly dividend. This is distributed in the months of September, April, September, September.

How secure is the dividend of Novo Nordisk A/S?

Novo Nordisk A/S paid dividends every year for the past 26 years.

What is the dividend of Novo Nordisk A/S?

For the upcoming 12 months, dividends amounting to 14.94 DKK are expected. This corresponds to a dividend yield of 1.94 %.

In which sector is Novo Nordisk A/S located?

Novo Nordisk A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Novo Nordisk A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Novo Nordisk A/S from 8/19/2024 amounting to 0.51 DKK, you needed to have the stock in your portfolio before the ex-date on 8/16/2024.

When did Novo Nordisk A/S pay the last dividend?

The last dividend was paid out on 8/19/2024.

What was the dividend of Novo Nordisk A/S in the year 2023?

In the year 2023, Novo Nordisk A/S distributed 11.15 DKK as dividends.

In which currency does Novo Nordisk A/S pay out the dividend?

The dividends of Novo Nordisk A/S are distributed in DKK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Novo Nordisk A/S stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank

Andere Kennzahlen von Novo Nordisk A/S

Our stock analysis for Novo Nordisk A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novo Nordisk A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.